Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 Vaccine, mRNA-1273.222
- Development stage
- Approved
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
COVID-19 Vaccine, mRNA-1273.222 is a bivalent messenger RNA (mRNA) vaccine developed by Moderna for use as a booster against COVID-19. It encodes the spike protein of both the original SARS-CoV‑2 strain and the Omicron BA.4/BA.5 subvariants, aiming to broaden immune protection against circulating variants of concern[1][7]. The vaccine is administered as a booster dose following completion of a primary vaccination series and has received emergency use authorization in multiple age groups, including adults and children as young as 6 months[3][5]. Clinical trials have demonstrated that mRNA‑1273.222 elicits superior neutralizing antibody responses against Omicron BA.4/BA.5 compared to previous monovalent boosters[2][6]. Its mechanism of action involves delivering synthetic mRNA encoding viral spike proteins via lipid nanoparticles; host cells translate this mRNA into antigenic proteins that stimulate an adaptive immune response.
- Brand names
- Spikevax
- Other names
- Moderna BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccineModerna bivalent booster (mRNA-1273.222)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COVID-19 Vaccine, mRNA-1273.222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 Vaccine, mRNA-1273.222.